Dr Hiley is an Associate Professor with tenure in Radiation Oncology at University
College London (UCL) and a Consultant Clinical Oncologist at University College
London Hospital (UCLH). He is the UK Clinical Director for Lung Cancer for
Genesiscare.

Dr Hiley specialises in the use of stereotactic radiotherapy (SBRT) for oligo metastatic
and oligo progressive disease for many types of cancer including but not
limited to breast, prostate, colorectal, gynaecological, sarcoma and lung.

He is an expert in all the non-surgical treatments for all types of lung cancer. He has expertise in chemotherapy, immunotherapy and radiotherapy including state of the art
radiotherapy techniques including Volumetric Arc Therapy (VMAT), Intensity
Modulated Radiotherapy (IMRT), Image Guided Radiotherapy (IGRT), Proton Therapy
and Stereotactic Radiotherapy (SBRT).

He specialises in reirradiation, the use of radiotherapy for patients who have
received prior radiotherapy, in the management of lung cancer and oligo
metastatic and oligo progressive disease of many different cancer types. .

He became a consultant in 2018 and is clinical lead of the clinical
oncology lung team at UCLH, UCLH Lead for Lung Proton Therapy, Deputy Lead of
Clinical Trials for the CRUK Lung Cancer Centre of Excellence, NIHR Clinical Research Network Speciality Research Lead Radiotherapy for North London and Deputy Chair of the National Cancer Research Institute Lugn Group. He heads a research group at the UCL
Cancer Institute focused on understanding resistance to radiation therapy.

He is the chief Investigator of the HIT-MESO study investigating the role
of hemi-thoracic proton radiotherapy for mesothelioma. He is the principal
investigator and national chief investigator for several academic and
commercial clinical trials in lung cancer. He has published in many of the
world's leading journals including NEJM, The Lancet, Nature and Cell. He is a
member of the expert group which authored the Radiotherapy for Lung Cancer
Royal College of Radiologists Consensus Statement.